Support for Multimodality Therapy in Some Patients With Follicular Lymphoma
Follicular lymphoma is classified into 3 histologic grades on the basis of the number of centroblasts per high-power field.
Non-Hodgkin Lymphoma
Consensus Panel on Maintenance Therapies Following Autologous Hematopoietic Cell Transplantation in Lymphoma
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Two Measures Independently Predict for NHL in Patients With HIV
Both a high HIV viral load and a low CD4 level independently predict for the risk of NHL in patients who have HIV.
BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency
Severe Neurotoxicity Following CAR-T Cell Therapy Associated With Poor Prognosis
CAR-T–related neurotoxicity was found to be associated with the presence of cytokine release syndrome.
“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
Ambient Benzene Exposure and Risk of Hematologic Malignancies
Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort.
Ibrutinib Plus Nivolumab in 4 Cohorts of Patients With R/R NHL or CLL
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma
Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.
